Vaxfab enterprises Limited has successfully completed the allotment of 13,28,861 equity shares following the conversion of warrants by investors. The board of directors approved this allotment during their meeting held on April 17, 2026, marking a significant capital expansion for the Ahmedabad-based company.

Allotment Details and Pricing Structure

The equity shares were allotted at a price of Rs. 21.02 per share, with each share carrying a face value of Rs. 10. The allotment was conducted on a preferential basis to three institutional investors who exercised their warrant conversion rights.

Investor-wise Allocation Breakdown

The warrant conversion was executed by three limited liability partnerships, with varying levels of participation in the conversion process.

Lankini Management Consultancy LLP emerged as the largest participant, converting 11,51,284 warrants while retaining 7,80,147 unconverted warrants. Sparkling Tradewing LLP fully converted all its eligible warrants, while Kushmanda Tradeline LLP retained 3 unconverted warrants.

Impact on Share Capital Structure

The warrant conversion has resulted in a substantial increase in the company's equity base. Following the allotment, Vaxfab Enterprises' paid-up equity share capital expanded to Rs. 22,20,00,270, comprising 2,22,00,027 equity shares of Rs. 10 face value each.

The newly allotted equity shares will rank pari-passu with existing equity shares, providing equal rights and privileges to the new shareholders. This expansion strengthens the company's capital foundation and provides additional financial resources for business operations.

Warrant Conversion Framework

The original warrants were issued with a conversion tenure not exceeding 18 months from the allotment date. The conversion process involved a two-stage payment structure, where investors initially paid Rs. 5.255 per warrant during the original allotment and subsequently paid Rs. 15.765 per warrant at the time of conversion to equity shares.

This successful warrant conversion demonstrates investor confidence in Vaxfab Enterprises' business prospects and provides the company with enhanced financial flexibility for future growth initiatives.

Vaxfab Enterprises has issued a clarification regarding its recent warrant conversion, correcting the total number of equity shares allotted from the previously announced figure. The company's board meeting held on March 17, 2026, approved the allotment of equity shares through warrant conversion at Rs. 21.02 per share, but a typographical error in the initial disclosure required correction.

Corrected Allotment Details

The company clarified that the correct number of equity shares allotted pursuant to warrant conversion is 27,33,902 shares instead of the previously stated 27,33,903 shares. This correction was necessitated due to an inadvertent typographical/clerical error in the original disclosure.

Regulatory Compliance and Clarification

The clarification was issued on April 14, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Director Nishant Gandhi (DIN: 09250907) signed the clarification notice, which was communicated to both BSE Limited and The Calcutta Stock Exchange Limited.

The company confirmed that except for the correction in the number of shares, all other particulars, terms and conditions of the allotment remain unchanged from the original board resolution.

Corporate Structure Impact

The warrant conversion represents a significant capital expansion for the Gujarat-based company. Each warrant carried conversion rights at Rs. 21.02 per share, and the newly allotted shares rank pari-passu with existing equity shares, providing equal rights and privileges to the warrant holders.

Vaxfab Enterprises, incorporated in 1983 with CIN L51100GJ1983PLC093146, has its registered office at Scarlet Gateway, Prahladnagar Corporate Road, Ahmedabad. The company maintains transparency in its disclosure practices by promptly correcting any inadvertent errors in regulatory filings.